Time-dependent changes in RPILD and mortality risk in anti-MDA5+DM patients: a cohort study of 272 cases in China

被引:33
作者
You, Hanxiao [1 ]
Wang, Lei [1 ]
Wang, Jiajia [1 ]
Lv, Chengyin [1 ]
Xu, Lingxiao [1 ]
Yuan, Fenghong [2 ]
Li, Ju [3 ]
Wu, Min [4 ]
Zhou, Shiliang [4 ]
Da, Zhanyun [5 ]
Qian, Jie [5 ]
Wei, Hua [6 ]
Yan, Wei [6 ]
Zhou, Lei [7 ]
Wang, Yan [7 ]
Yin, Songlou [8 ]
Zhou, Dongmei [8 ]
Wu, Jian [9 ]
Lu, Yan [10 ]
Su, Dinglei [11 ]
Liu, Zhichun [12 ]
Liu, Lin [13 ]
Ma, Longxin [14 ]
Xu, Xiaoyan [15 ]
Zang, Yinshan [16 ]
Liu, Huijie [17 ]
Ren, Tianli [18 ]
Wang, Fang [19 ]
Zhang, Miaojia [1 ]
Tan, Wenfeng [1 ]
机构
[1] Nanjing Med Univ, Dept Rheumatol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Rheumatol & Immunol, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China
[3] Huaian First Peoples Hosp, Dept Rheumatol, Huaian, Jiangsu, Peoples R China
[4] First Peoples Hosp Changzhou, Dept Rheumatol, Changzhou, Jiangsu, Peoples R China
[5] Nantong Univ, Dept Rheumatol, Affiliated Hosp, Nantong, Jiangsu, Peoples R China
[6] Northern Jiangsu Peoples Hosp, Dept Rheumatol, Yangzhou, Jiangsu, Peoples R China
[7] Changzhou 2 Peoples Hosp, Dept Rheumatol, Changzhou, Jiangsu, Peoples R China
[8] Xuzhou Med Univ, Dept Rheumatol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[9] Soochow Univ, Dept Rheumatol, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
[10] Jiangsu Prov Hosp Chinese Med, Dept Rheumatol, Nanjing, Jiangsu, Peoples R China
[11] Nanjing First Hosp, Dept Rheumatol, Nanjing, Jiangsu, Peoples R China
[12] Soochow Univ, Dept Rheumatol, Affiliated Hosp 2, Suzhou, Jiangsu, Peoples R China
[13] Xuzhou Cent Hosp, Dept Rheumatol, Xuzhou, Jiangsu, Peoples R China
[14] Yancheng 1 Peoples Hosp, Dept Rheumatol, Yancheng, Jiangsu, Peoples R China
[15] Southeast Univ, Dept Rheumatol, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China
[16] Nanjing Med Univ, Dept Rheumatol, Affiliated Suqian Peoples Hosp 1, Suqian, Jiangsu, Peoples R China
[17] First Peoples Hosp Lianyungang, Dept Rheumatol, Lianyungang, Jiangsu, Peoples R China
[18] Wuxi 2 Peoples Hosp, Dept Rheumatol, Wuxi, Jiangsu, Peoples R China
[19] Nanjing Med Univ, Dept Cardiol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
DM; MDA5; interstitial lung disease; RPILD; time-dependent; INTERSTITIAL LUNG-DISEASE; AMYOPATHIC DERMATOMYOSITIS; CLINICAL SPECTRUM; JAPANESE PATIENTS; RIG-I; POLYMYOSITIS; UTILITY; MDA5;
D O I
10.1093/rheumatology/keac450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Anti-melanoma differentiation-associated gene 5 positive (anti-MDA5+) DM has a close relationship with rapidly progressive interstitial lung disease (RPILD) and is associated with high mortality. However, data regarding the time-dependent risk of RPILD and deaths during disease progression are limited. We conducted this study to investigate whether the risk of RPILD and death were time-dependent or not in anti-MDA5+ DM. Methods We assessed a cohort of 272 patients with anti-MDA5+ DM. The clinical characteristics of patients with anti-MDA5+ were collected, and COX regression was used to analyse independent risk factors for RPILD and death. We also described changes in risk of RPILD and death over time and their potential clinical implications. Results There were 272 anti-MDA5+ DM patients enrolled in this study. According to the multivariate cox regression analysis, short disease course, high CRP level, anti-Ro52 positive and anti-MDA5 titre (++similar to+++) were independent risk factors of RPILD. High creatine kinase level, high CRP level and RPILD were independent risk factors for death, and >90% RPILD and 84% mortality occurred in the first 6 months after disease onset. Notably, the first 3 months is a particularly high-risk period, with 50% of RPILD and 46% of deaths occurring. Hazards regarding RPILD and mortality diminished over time during a median follow-up of 12 months. Conclusion These results suggest significant, time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients, providing a cut-off time window to estimate disease progression and poor prognosis.
引用
收藏
页码:1216 / 1226
页数:11
相关论文
共 34 条
  • [1] Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy
    Abe, Yoshiyuki
    Kusaoi, Makio
    Tada, Kurisu
    Yamaji, Ken
    Tamura, Naoto
    [J]. RHEUMATOLOGY, 2020, 59 (04) : 767 - 771
  • [2] POLYMYOSITIS AND DERMATOMYOSITIS .2.
    BOHAN, A
    PETER, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) : 403 - 407
  • [3] Cavagna L, 2022, CLIN EXP RHEUMATOL, V40, P274, DOI 10.55563/clinexprheumatol/di1083
  • [4] Utility of Anti-Melanoma Differentiation-Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta-Analysis
    Chen, Zhiyong
    Cao, Mengshu
    Nieves Plana, Maria
    Liang, Jun
    Cai, Hourong
    Kuwana, Masataka
    Sun, Lingyun
    [J]. ARTHRITIS CARE & RESEARCH, 2013, 65 (08) : 1316 - 1324
  • [5] What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?
    De Lorenzis, Enrico
    Natalello, Gerlando
    Gigante, Laura
    Verardi, Lucrezia
    Bosello, Silvia Laura
    Gremese, Elisa
    [J]. AUTOIMMUNITY REVIEWS, 2020, 19 (11)
  • [6] Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?
    Giannini, Margherita
    Ohana, Mickael
    Nespola, Benoit
    Zanframundo, Giovanni
    Geny, Bernard
    Meyer, Alain
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (03)
  • [7] Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis
    Gono, Takahisa
    Kawaguchi, Yasushi
    Satoh, Takashi
    Kuwana, Masataka
    Katsumata, Yasuhiro
    Takagi, Kae
    Masuda, Ikuko
    Tochimoto, Akiko
    Baba, Sayumi
    Okamoto, Yuko
    Ota, Yuko
    Yamanaka, Hisashi
    [J]. RHEUMATOLOGY, 2010, 49 (09) : 1713 - 1719
  • [8] Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review
    Huang, Kun
    Vinik, Ophir
    Shojania, Kam
    Yeung, James
    Shupak, Rachel
    Nimmo, Michael
    Avina-Zubieta, J. Antonio
    [J]. RHEUMATOLOGY INTERNATIONAL, 2019, 39 (11) : 1971 - 1981
  • [9] Association of Cytomegalovirus Infection With Anti-MDA5 Antibody-Positive Dermatomyositis: A Prospective Cohort Study
    Huang, Linlin
    Zhu, Wenbo
    Ye, Yan
    Wu, Xiaoping
    Yan, Qingran
    Wang, Zhiqing
    Lin, Yanwei
    Chen, Sheng
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [10] High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center
    Huang, Linlin
    Fu, Qiong
    Ye, Yan
    Lin, Yanwei
    Yan, Qingran
    Chen, Sheng
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)